Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine

Lancet

Volumn 350, Issue 9091, 1997, Pages 1569-1577

  Olin, Patrick ^a   Rasmussen, Finn ^a   Gustafsson, L ^a   Hallander, Hans O ^a   Heijbel, Harald ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; FEVER; FIMBRIA; HUMAN; IMMUNOGENICITY; INFANT; INFANTILE HYPOTONIA; INTRAMUSCULAR DRUG ADMINISTRATION; ITALY; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SWEDEN; UNITED KINGDOM; UNITED STATES;

EID: 0031590627     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06508-2     Document Type: Article

References (28)

1. Greco D, Salmaso S, Mastrantonio P, et al. Clinical efficacy, immunogenicity and safety of two acellular and one whole-cell pertussis vaccines: results from the Italian trial. N Engl J Med 1996; 334: 341-48.
2. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55.
3. Halsey NA. New developments with pertussis vaccines. Pediatrics 1995; 96: 970-71
4. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334: 391-92.
5. Poland GA. Accelular pertussis vaccines: new vaccines for an old disease. Lancet 1996; 347: 209-10.
6. Plotkin S, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997; 16: 508-17.
7. Schneerson R, Robbins JB, Taranger J, Lagergård T, Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 1996; 348: 1289-92.
8. Olin P. The best acellular pertussis vaccines are multi-component. Pediatr Infect Dis J 1997; 16: 517-19.
9. Olin P, Rasmussen F, Gottfarb P. Vaccination schedule and protection: simultaneous vaccination and safety-experiences from recent controlled pertussis trials. Int J Infect Dis 1997; 1: 143-47.
10. Olin P, Gustafsson L, Rasmussen F, Hallander H, Heijbel H, Gottfarb P. Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Stockholm: Swedish Institute for Infectious Disease Control (SMI-tryck), 1997; 116: 1-70.
11. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protection capacity and immunogenicity of the 69 kD outer membrane protein of Bordetella pertussis. J Exp Med 1990; 171: 63-73.
12. Cody Cl, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650-60.
13. WHO meeting on case definition of pertussis. Geneva, 10-11 Jan, 1991. Geneva: WHO, MIN/EPI/PERT/91. 1: 4-5.
14. Reizenstein E, Möllby R, Blackwelder WC, Ljungman M, Kühn I, Hallander HO. Comparison of five calculation modes for antibody ELISA using pertussis serology as model. J Immunol Methods 1995; 183: 279-90.
15. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccine: technical report, trial I, with results of preplanned analysis of safety, efficacy and immunogenicity. Stockholm: Swedish Institute for Infectious Disease Control (SMI-tryck), 1995; 105: 1-70.
16. Meade BD, Deforest A, Edwards KM, et al. Description and evaluation of serologic assays used in a muilticenter trial of acellular pertussis vaccines. Pediatrics 1995; 96: 570-75.
17. Lynn F, Reed GF, Meade BD. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 1996; 3: 689-700.
18. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley and Sons, 1980.
19. Hallander HO, Storsaeter J, Möllby R. Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial. J Infect Dis 1991; 163: 1046-54.
20. Storsaeter J, Olin P. Efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992; 10: 142-44.
21. Medical Research Council. The prevention of whooping-cough by vaccination. BMJ 1951; i: 1463-71.
22. Pollock TM, Miller E, Lobb J, Smith P. Efficacy of pertussis vaccination in England: report from the PHLS epidemiological research laboratory and 21 area health authorities. BMJ 1982; 285: 357-59.
23. Blennow M, Olin P, Granström M, Bernier RH. Protective efficacy of a whole cell pertussis vaccine. BMJ 1988; 296: 1570-72.
24. Preston NW. Change in prevalent serotype of pertussis infection in Britain. Lancet 1985; i: 510.
25. Miller E, Farrington CP. The current epidemiology of pertussis in the developed world: UK and West Germany. Tokai J Exp Clin Med 1988; 13 (suppl): 97-101.
26. Rappuoli R. Rational design of vaccines: the recombinant pertussis vaccine induces early and long-lasting protection. Nat Med 1997; 3: 374-76.
27. Taranger J, Trollfors B, Knutsson N. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial. Dev Biol Stand 1996; 89: 105-08.
28. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 39 (suppl): 557-66.